tag johnson-and-johnson 
pharmaphorum
AUGUST 25, 2022
Johnson & Johnson has its first worldwide regulatory approval – in the EU – for Tecvayli, one of two much-anticipated bispecific antibodies the drugmaker has developed for patients with multiple myeloma. Tecvayli previously scored a priority medicines (PRiME) designation from the EMA and a breakthrough-therapy tag from the FDA.
pharmaphorum
AUGUST 21, 2022
That status goes to Johnson & Johnson’s Spravato (esketamine), which was approved in March 2019 and is administered as a nasal spray twice a week for four weeks. In this product, bupropion is designed to increase levels of dextromethorphan in the blood and extend its half-life.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
MARCH 23, 2022
Vyvgart (efgartigimod alfa) became the first drug in the FcRn class to be approved by the FDA last December, and despite a $225,000 annual price tag is predicted to make relatively modest sales in its IV version, which will compete with other IV gMG drugs like AstraZeneca/Alexion’s C5 inhibitor Soliris (eculizumab). in the IV arm.
pharmaphorum
NOVEMBER 24, 2022
Johnson & Johnson’s Spravato therapy for treatment-resistant depression (TRD) hasn’t made the impact the company hoped for in the market, and it is looking to new clinical results to accelerate its take-up. and 17.6%, respectively, according to J&J’s pharma unit Janssen. and 14.1%, respectively.
pharmaphorum
JULY 25, 2022
The EMA’s human medicines committee has recommended approval of Johnson & Johnson’s Tecvayli as a fourth-line therapy for multiple myeloma , joining a growing group of BCMA-targeted therapies for the blood cancer.
Pharmaceutical Technology
MAY 15, 2023
Innovation S-curve for the pharmaceutical industry Peptide nano-particle conjugates is a key innovation area in the pharmaceutical industry By tagging peptides with nanoparticles, peptide nano-particle conjugates allow enhanced control over their biological behaviour, overcoming intrinsic limitations of the individual materials.
pharmaphorum
JUNE 2, 2022
Evaluate expects five big pharma companies to be reliant on orphan drugs to provide 20% or more of their sales by 2026, with Johnson & Johnson topping the list at an estimated 39% of all sales. As covered in a previous article , the importance of R&D to develop treatments for rare diseases is high. The price is right.
Expert insights. Personalized for you.
98 
Let's personalize your content